Samsara BioCapital
Overview
Samsara BioCapital is a life sciences investment firm that focuses on translating cutting-edge biology into new therapies to treat patients with unmet medical needs across all stages of public and private companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Nura Bio | Jun 2026 | Series B | Co-investor |
| Memento Medicines | Jun 2026 | Series A | Co-investor |
| Coultreon Biopharma | Apr 2026 | Series A | Co-investor |
| Sidewinder | Apr 2026 | Series B | Co-investor |
| Sidewinder Therapeutics | Apr 2026 | Series B | Co-investor |
Key People
Alan Eisenberg
Venture Partner
Betsy Santos
Venture Partner and Chief People Officer, Chief People Officer
Dan Spiegelman
Venture Partner
Dolca Thomas
Venture Partner Senior Advisor
Eric Dobmeier
Venture Partner
Gunaretnam Rajagopal
Venture Partner
James Edwards
Venture Partner, Samsara BioCaptial
John Orwin
Venture Partner
Robert Baffi
Venture Partner
Stephen Shuttleworth
Venture Partner
Cory Freedland
Partner
Tom Bumol
Member, Board Of Directors
Abraham Bassan
Principal
Mitchell Mutz
Senior Principal
Ehi Akhirome
Investor
Matt Eckler
Healthcare Investor
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
